Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age14+
SponsorDaihong Liu
About this trial
The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.
Eligibility criteria
Qualifiers
Age: Over 14 years old
Diagnosed with multiple myeloma accompanied by renal dysfunction, received ≥ 2 courses of clinical first-line treatment, evaluated efficacy above PR, and predicted survival of more than three months.
ECOG physical status score 0-2 or KPS score>80 points
Having sufficient venous access for single or intravenous blood collection, and no other blood cells Separation contraindications
Disqualifiers
Pregnant or lactating women (the safety of this treatment for unborn babies is unknown, and the assessment of pregnancy status for female participants is negative in serum or urine pregnancy tests within 48 hours prior to infusion);
Any uncontrollable active infection;
Presence of active hepatitis B or C virus infection;
HIV/AIDS infection;
Trial design
Treatments tested in this trial
- PD-1Ab21-BCMA CAR-T cell immunotherapy
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Daihong Liu
Lead sponsor
Chinese PLA General Hospital
Sponsor institution
Source ClinicalTrials.gov